Advances in small-molecule drug discovery for triple-negative breast cancer.
Triple-negative breast cancer (TNBC) is a subtype of poor prognosis, highly invasive and difficult-to-treat breast cancers accounting for approximately 15% of clinical cases. Given the poor outlook and lack of sustained response to conventional therapies, TNBC has been the subject of intense studies on new therapeutic approaches in recent years. The development of targeted cancer therapies, often in combination with established chemotherapy, has been applied to a number of new clinical studies in this setting in recent years. This review will highlight recent therapeutic advances in TNBC, focusing on small-molecule drugs and their associated biological mechanisms of action, and offering the possibility of improved prospects for this patient group in the near future.
School of Pharmacy & Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, Wales, UK.
Nelly
N
Fosu-Mensah
School of Pharmacy & Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, Wales, UK.
María Sánchez
MS
Peris
Cardiff China Medical Research Collaborative, Institute of Cancer & Genetics, School of Medicine, Heath Park, Cardiff University, Cardiff, CF10 3AX, Wales, UK.
Hoi Ping
HP
Weeks
Cardiff China Medical Research Collaborative, Institute of Cancer & Genetics, School of Medicine, Heath Park, Cardiff University, Cardiff, CF10 3AX, Wales, UK.
Jun
J
Cai
School of Pharmacy & Pharmaceutical Sciences, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, Wales, UK.
Andrew D
AD
Westwell
D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D055808:Drug Discovery; D006801:Humans; D015394:Molecular Structure; D054852:Small Molecule Libraries / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D054852:Small Molecule Libraries